Form 4 for MDGL MADRIGAL PHARMACEUTICALS, INC.
Accepted 2024-01-18 00:00:00 ET · period of report 2024-01-16 · accession 0000950170-24-005294 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-01-18 | 2024-01-16 | MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev | F - Tax | $243.92 | -550 | 5,117 | -10% | -$134.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-16 | F | D | 550 | $243.92 | 5,117 | D | — | — |